Glaucoma

BMP and Activin Membrane Bound Inhibitor Regulates the Extracellular Matrix in the Trabecular Meshwork

Humberto Hernandez, J. Cameron Millar, Stacy M. Curry, Abbot F. Clark, and Colleen M. McDowell

Department of Pharmacology and Neuroscience, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States

Correspondence: Colleen M. McDowell, Department of Pharmacology & Neuroscience, North Texas Eye Research Institute, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA; Colleen.McDowell@unthsc.edu.

Submitted: November 2, 2017
Accepted: March 22, 2018

Citation: Hernandez H, Millar JC, Curry SM, Clark AF, McDowell CM. BMP and activin membrane bound inhibitor regulates the extracellular matrix in the trabecular meshwork. Invest Ophthalmol Vis Sci. 2018;59:2154–2166. https://doi.org/10.1167/iovs.17-23282

Purpose. The trabecular meshwork (TM) has an important role in the regulation of aqueous humor outflow and IOP. Regulation of the extracellular matrix (ECM) by TGFβ2 has been studied extensively. Bone morphogenetic protein (BMP) and activin membrane-bound inhibitor (BAMBI) has been shown to inhibit or modulate TGFβ2 signaling. We investigate the role of TGFβ2 and BAMBI in the regulation of TM ECM and ocular hypertension.

Methods. Mouse TM (MTM) cells were isolated from B6;129S1-Bambi<sup>tm1Jian/J</sup> flox mice, characterized for TGFβ2 and dexamethasone (DEX)-induced expression of fibronectin, collagen-1, collagen-4, laminin, α-smooth muscle actin, cross-linked actin networks (CLANs) formation, and DEX-induced myocilin (MYOC) expression. MTM cells were transduced with Ad5.GFP to identify transduction efficiency. MTM cells and mouse eyes were transduced with Ad5.Null, Ad5.Cre, Ad5.TGFβ2, or Ad5.TGFβ2 + Ad5.Cre to evaluate the effect on ECM production, IOP, and outflow facility.

Results. MTM cells express TM markers and respond to DEX and TGFβ2. Ad5.GFP at 100 MOI had the highest transduction efficiency. Bambi knockdown by Ad5.Cre and Ad5.TGFβ2 increased fibronectin, collagen-1, and collagen-4 in TM cells in culture and tissue. Ad5.Cre, Ad5.TGFβ2, and Ad5.TGFβ2 + Ad5.Cre each significantly induced ocular hypertension and lowered aqueous humor outflow facility in transduced eyes.

Conclusions. We show for the first time to our knowledge that knockdown of Bambi alters ECM expression in cultured cells and mouse TM, reduces outflow facility, and causes ocular hypertension. These data provide a novel insight into the development of glaucomatous TM damage and identify BAMBI as an important regulator of TM ECM and ocular hypertension.

Keywords: BAMBI, TGFβ2, BMP, trabecular meshwork, ocular hypertension, extracellular matrix

Glaucoma is the second leading cause of blindness worldwide, affecting approximately 70 million individuals. It is a heterogeneous group of optic neuropathies, characterized by the loss of retinal ganglion cells (RGCs) leading to irreversible vision loss and blindness. Primary open angle glaucoma (POAG) affects the drainage angle of the eye and is associated with elevated IOP. Elevated IOP is due to increased outflow resistance at the trabecular meshwork (TM). Glaucomatous changes at the TM include loss of TM cellularity, thickening of the TM beams, and increased extracellular matrix (ECM) production, deposition, and remodeling. Current treatment options for POAG patients generally involve reducing IOP with pharmacologic drugs that do not target the pathologic processes occurring at the TM. The molecular mechanisms responsible for changes to the TM and aqueous humor outflow resistance needs further investigation.

TGFβ2 is one of the most studied growth factors and the most common isoform in the eye. Studies have shown that aqueous humor levels of TGFβ2 are elevated in POAG patients. It is well established that TGFβ2 alters the ECM composition and ECM crosslinking of the TM. We and others have demonstrated previously that TGFβ2 elevates IOP in the anterior segment perfusion organ culture models and Ad5.TGFβ2 induces ocular hypertension in mice. It is well known that TM cells express and secrete TGFβ2. TGFβ2-induced changes to the TM occur through the canonical SMAD and non-SMAD signaling pathways, and the canonical SMAD pathway is essential for TGFβ2-induced ocular hypertension in mice. The canonical signaling pathway is initiated when TGFβ2 binds type II receptors (TGFβRII), which assembles, activates, and phosphorylates type I receptors (TGFβRI). Activated TGFβRI subsequently phosphorylates SMAD2/3 and leads to the association of SMAD4 into a complex. This complex interacts with coactivators or corepressors to regulate gene transcription. To understand the development of ocular hypertension, the homeostatic regulatory molecules of TGFβ2 and signaling molecules must be evaluated.

Bone morphogenetic proteins (BMPs) are a family of growth factors involved in regulation of the ECM. BMPs can suppress TGFβ2-induced ECM deposition, the BMP antagonist gremlin elevates IOP in perfusion cultured anterior segments, and overexpression of gremlin in mouse eyes and BMP2 in rats causes ocular hypertension, suggesting that BMP signaling is required for regulating outflow. Similar to TGFβ2, BMP signaling requires two types of transmembrane serine/
threonine receptors, type I (BMPR-I) and type II (BMPR-II). BMPR-II is used most commonly for BMP signaling and is the target of BMP antagonists. The activated BMPR-I and BMPR-II complex results in phosphorylation of SMAD1, SMAD5, or SMAD8. The phosphorylated SMAD1/5/8 complex associates with SMAD4, and the complex translocates to the nucleus and associates with coactivators or corepressors to regulate gene transcription. We have shown previously that TM cells express BMPs and their receptors; BMP2, BMP4, BMP5, BMP7, BMP-RIA, BMP-RIB, and BMP-RII. A better understanding of the regulatory mechanisms involved in BMP and TGFβ2 signaling is necessary for the development of novel disease modifying therapeutic treatments for POAG patients.

BMP and activin membrane-bound inhibitor (BAMBI) is a transmembrane glycoprotein related to the TGFβ-family type I receptors, but lacks an intracellular kinase domain. BAMBI has been shown to be important in embryonic development as it is coexpressed with BMP4 and BAMBI expression is induced by BMP4, suggesting a negative mechanistic feedback loop. BAMBI is evolutionarily conserved from fish to humans, with a mouse and human homology of 85%. BAMBI has been shown to inhibit BMP, activin, and TGFβ signaling. BAMBI can interact with BMP receptors directly and antagonize BMP signaling, as well as interact directly with TGFβ receptors and antagonize TGFβ signaling. BAMBI also can interact with BMP and TGFβ signaling pathways through other different mechanisms. BAMBI can form a ternary complex with SMAD7/ALK5/TGFβRI and inhibit the interaction between ALK5/TGFβRI and SMAD3; thus, impairing SMAD3 activation. BAMBI has also been shown to cotranslocate with SMAD2/3 into the nucleus upon TGFβ treatment and modulate TGFβ signaling. The human BAMBI promoter contains the elements that directly associate with SMAD3 and SMAD4, and these elements are critical for the TGFβ responsiveness to the BAMBI promoter. BAMBI has been shown to inhibit fibrogenesis through suppression of TGFβ-induced collagen-I expression. Knockdown of Bamdi expression enhances canonical and noncanonical TGFβ signaling. Recently, we have shown that BAMBI is expressed in human TM cells and is downregulated by the presence of TGFβ2 (5 ng/mL) at 24 hours. These data suggest that BAMBI is an important molecule in TGFβ signaling regulation.

Toll-like receptor 4 (TLR4) signaling has been identified as a regulator of BAMBI expression. TLR4 activation by lipopolysaccharide (LPS) downregulates BAMBI, which enhances TGFβ signaling leading to increased ECM production via a SMAD-dependent pathway. BAMBI downregulation by TLR4 is regulated by the MyD88-MAF-dependent pathway. The transcriptional repression of BAMBI by NF-kB p50 enhances TGFβ signaling in hepatic satellite cells. In addition, TLR4 enhances TGFβ signaling and hepatic fibrosis by downregulation of BAMBI. These data suggest that TLR4 is an important regulator of BAMBI expression in the context of TGFβ2-TLR4 signaling crosstalk. Further experiments are needed to determine the exact mechanistic role of BAMBI in TGFβ2-TLR4 signaling; however, these data suggest that activation of TLR4 downregulates BAMBI leading to TGFβ fibrogenesis.

BAMBI also has been associated with the pathogenesis of several human diseases, including colorectal carcinoma, hepatocellular carcinomas, gastric carcinoma, hepatic fibrosis, and scleroderma. Bamdi knockdown has been shown to increase TGFβ signaling in a model of diabetic glomerular disease where overexpression of TGFβ has been correlated with the disease pathology. We also recently have identified TGFβ2-TLR4 signaling crosstalk as an important regulator of the ECM in the TM and ocular hypertension. Here, we demonstrated that TGFβ2 regulates BAMBI expression in TM cells, knockdown of Bamdi induces ECM production in TM vitro and in vivo, and knockdown of Bamdi in the mouse TM induces ocular hypertension and outflow resistance.

Materials and Methods

Mouse TM Cell Culture

Mouse TM (MTM) cells were isolated, cultured, and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen-Gibco Life Technologies, Grand Island, NY, USA) containing 15% fetal bovine serum (FBS; Atlas Biologicals Products, Fort Collins, CO, USA) and supplemented with penicillin (100 units/mL), streptomycin (0.1 mg/mL), and L-glutamine (0.292 mg/mL; Gibco BRL Life Technologies). MTM cells were isolated as described below. All experiments were performed on cells within 10 passages.

B6;129S1-BamdiJian/J Mice

All experiments were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the University of North Texas Health Science Center (UNTHSC; Fort Worth, TX, USA) Institutional Animal Care and Use Committee (IACUC) Guidelines and Regulations. B6;129S1-BamdiJian/J conditional knockout mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and subsequently bred at UNTHSC. All mice were 3 to 5 months old at the start of the experiment. All animals were housed in the UNTHSC vivarium. MTM cells were isolated from B6;129S1-BamdiJian/J as stated. Adenovirus serotype 5 (Ad5) viral vector expressing bioactivated human TGFβ2 (Vector Biolabs, Malvern, PA, USA) was used to knockdown Bamdi, and Ad5.Null vector (Vector Biolabs) was used as a negative control. Briefly, 2.5 μL of 2.5 × 107 plaque-forming units (pfu) was injected intravitreally into one eye, and the contralateral eyes used as negative controls.

Mouse TM Cells Isolation and Characterization

Intracameral injections, anterior segment dissections, and magnetic bead isolation of MTM cells was performed according to our established protocol with modifications. It is well established that TM cells have phagocytic properties. Briefly, a single culture of TM cells was established from the B6;129S1-BamdiJian/J mouse strain by dissecting TM rings from eight eyes. TM rings were placed in collagenase...
at 37°C for 2 hours. After digestion, cells were spun down (600 g for 10 minutes), resuspended in PBS and passed through a 100 μM cell strainer (Thermo Fisher Scientific, Worcester, MA, USA). The flow through was transferred to Eppendorf tubes and attracted to a magnet on the tube hinge side for 5 minutes. The nonbinding cells were transferred to another Eppendorf tube and attracted cells were resuspended in PBS. This process was repeated at least three times until the Eppendorf tubes containing attracted cells had no visible pigment, after which complete medium was added and cells transferred to a 96-well plate. Isolated MTM cells were cultured in 24-well plates on coverslips and allowed to reach confluency. Cells were treated for 96 hours (protein expression) or 7 days (cross-linked actin networks [CLANs] characterization) with TGFβ2 (5 ng/mL), culture medium (TGFβ2 control), dexamethasone (DEX; 100 nM), or ethanol (ETOH; vehicle control) in serum-free medium. Culture medium was changed every other day. Cells were processed for immunocytochemistry and CLANs counted as described previously. CLAN formation rate was expressed as the ratio of CLAN-positive cells/total number of 4',6-diamidino-2-phenylindole (DAPI)-stained cells. Cells were determined to be CLAN-positive if they contained at least one CLAN. For each treatment, five regions in each coverslip and five to six coverslips were counted.

**FIGURE 2.** Characterization of MTM cells for the expression of fibronectin, collagen-1, collagen-4, laminin, and α-smooth muscle actin. MTM cells were grown to confluency, treated for 96 hours with control (serum-free medium; A, E, I, M, Q), TGFβ2 (5 ng/mL; B, F, J, N, R), ETOH (vehicle control for DEX; C, G, K, O, S), or DEX (100 nM; D, H, L, P, T). Control-treated cells each expressed basal levels of fibronectin (A, C), collagen-1 (E, G), collagen-4 (I, K), laminin (M, O), and α-smooth muscle actin (Q, S). TGFβ2 and DEX induced the expression of fibronectin (B, D), collagen-1 (F, H), collagen-4 (J, L), laminin (N, P), and α-smooth muscle actin (R, T) compared to control. N = 3 independent experiments in the B6;129S1-Bambi<sup>−/−</sup>/J mouse TM cell strain.
BAMBI Regulates ECM in the TM

Immunocytochemistry

Mouse TM cells were seeded in 24-well plates on coverslips. After completing the treatment time course, cells were washed with PBS, fixed with 4% paraformaldehyde (PFA), permeabilized with 0.05% Triton X-100 in PBS, and blocked using Superblock Blocking Buffer in PBS (Thermo Fisher Scientific) for 60 minutes at room temperature. Cells were labeled overnight at 4°C with rabbit anti-fibronectin (EMD Millipore, Billerica, MA, USA) 1:500 dilution, anti-laminin (Novus Biologicals, LL, Littleton, CO, USA) 1:250 dilution, anti-collagen-1 (Novus Biologicals) 1:250 dilution, anti-collagen-4 (Novus Biologicals) 1:350 dilution, and α-smooth muscle actin (Abcam, Cambridge, MA, USA) 1:500 dilution in Superblock Blocking Buffer in PBS (Thermo Fisher Scientific). Treatment without the primary antibodies was used as negative controls (Supplemental Fig. S1). Coverslips were incubated for 2 hours using Alexa Fluor-labeled anti-rabbit or anti-mouse antibodies (Life Technologies, Carlsbad, CA, USA) 1:1000 dilution. To label CLANs, MTM cells were probed for filamentous actin (F-actin) using Alexa Fluor 488 phalloidin (Thermo Fisher Scientific) 1:250 dilution. Coverslips were mounted onto slides with Prolong Gold mounting medium containing DAPI (Invitrogen-Molecular Probes, Carlsbad, CA, USA). Image acquisition was performed using the Keyence BZ-X700 fluorescence microscope (Keyence Corporation of America, Itasca, IL, USA). Images were taken either at ×100, ×200, ×400, or ×600 magnification, with each presented Figure containing its corresponding scale bar. Mean fluorescent intensity/area for MTM cells was measured and analyzed using the NIS Elements software (Nikon, Tokyo, Japan).

Immunohistochemistry of Mouse Eyes

To evaluate early changes in the TM, an initial cohort of mice were transduced with viral vectors, Ad5.Null (n = 7), Ad5.Cre (n = 15), and Ad5.TGFβ2 (n = 9), and harvested 11-days after injection. IOP was recorded at 10-days postinjection. Eyes were fixed in 4% PFA overnight, embedded in paraffin, cut into 5 μm sections, and transferred to glass slides. Deparaffinization was performed by washing two times with xylene, 100% ethanol, 95% ethanol, and 50% ethanol for 2 minutes each. Slides then were soaked in PBS for 5 minutes. Tissues were blocked using Superblock Blocking Buffer in PBS (Thermo Fisher Scientific) for 60 minutes. Rabbit anti-fibronectin (EMD Millipore) 1:500 dilution, rabbit anti-collagen-1 (Novus Biologicals, LL) 1:250 dilution, mouse anti-collagen-4 (Sigma-Aldrich Corp., St. Louis, MO, USA) 1:250 dilution, and mouse anti-BAMBI (Abnova; Walnut, CA, USA) 1:250 dilution, were used as primary antibodies, followed by Alexa-Fluor-labeled anti-rabbit or anti-mouse antibodies (Life Technologies, Carlsbad, CA, USA) 1:500 dilution. Prolong Gold mounting medium containing DAPI (Invitrogen-Molecular Probes) was used to mount the slides, and sections were imaged using the Keyence BZ-X700 fluorescence microscope (Keyence Corporation of America, Itasca, IL, USA). All images were taken at ×100 magnification; scale bars represent 100 μm.

Western Blot Analysis

Western blot studies were performed as described previously. Briefly, MTM cells were treated as stated above. Conditioned medium samples were prepared as follows: conditioned medium (30 μL) and ×4 Laemmli Buffer (10 μL; Bio-Rad Laboratories, Hercules, CA, USA) were combined for a total volume of 40 μL. Samples were boiled for 10 minutes followed by separation using 12% SDS-PAGE. To verify equal loading for CM samples, gels were stained with Gel Code Blue Stain.
Reagent (Thermo Fisher Scientific). Proteins were transferred to polyvinylidene fluoride (PVDF) membranes (EMD Millipore), and membranes blocked with Superblock Blocking Buffer in TBS (Thermo Fisher Scientific). Membranes were immunolabeled overnight at 4°C with rabbit anti-fibronectin antibody (EMD Millipore) dilution 1:1000. Blots were incubated for 1 hour with horseradish peroxidase (HRP) conjugated goat anti-rabbit secondary antibody (1:1000; Pierce Biotechnology, Inc., Rockford, IL, USA) diluted in Superblock Blocking Buffer in TBS. Immunolabeled signals were developed using Clarity Western ECL Substrate, and blot images were acquired using ChemiDoc Touch Imaging System (Bio-Rad Laboratories). Each experiment was repeated three times. Densitometry analysis of Western immunoblot images was used to determine changes in protein content after treatment. Band intensity for fibronectin was measured using Image Lab Software (Bio-Rad Laboratories). Fold change was compared to Ad5.Null and represented as the mean ± SEM. Statistical significance was determined by 1-way ANOVA and Tukey post hoc analysis comparing all treatments.

IOP Measurements

After intravitreal injection of 2.5 μL (2.5 × 10^7 pfu) Ad5.Null (n = 7 mice), Ad5.Cre (n = 9 mice), Ad5.TGFβ2 (n = 10 mice), or Ad5.Cre + Ad5.TGFβ2 (n = 10 mice), IOP was measured as described previously for 56 days after injection.19–21 Briefly, IOP was measured under isoflurane anesthesia using the Tonolab tonometer (Colonial Medical Supply, Franconia, NH, USA). All IOP measurements were performed during the same time period of the light-on phase. Statistical significance was determined by Student’s paired t-test at each time point comparing the injected and contralateral uninjected control eyes.

Aqueous Humor Outflow Facility

To evaluate the effect of Ad5.Cre and Ad5.TGFβ2 on aqueous humor outflow rate in B6;129S1-Bambi tm1Jian/J mice, three to five mice were used for outflow facility after the 56-day IOP time-course as described previously.72,73 Briefly, eyes of anesthetized mice were cannulated intracamerally with a 30-gauge steel needle inserted through the peripheral cornea.
approximately 1 to 2 mm from the limbus and pushed toward the region of the opposing chamber angle. The needle was connected by tubing to an in-line pressure transducer for continuous determination of pressure within the system. The opposing terminal of the pressure transducer was connected by tubing to a 50 μL glass micro syringe loaded into a microdialysis infusion pump. The pump was switched on and set to a flow rate of 0.1 μL/min. The pump remained running until the pressure in the system was stabilized. Flow rates were then increased sequentially to 0.4, and 0.5 μL/min, and stabilized pressure values at each flow rate were recorded. For each eye, aqueous humor outflow facility (μL/min/mm Hg) was calculated as the reciprocal of the slope of the respective pressure-flow rate curves.

RESULTS

Isolation and Characterization of Mouse TM Cells

Extracellular matrix deposition at the TM is a major factor involved in the development of ocular hypertension. To better understand the role of BAMBI in ECM deposition in TM cells, MTM cells were isolated from B6;129S1-Bambitm1Jian/J mice using magnetic beads (Figs. 1A, 1B). We used our established protocol56 and removed the pigment during the isolation process (Fig. 1). MTM cells were characterized for the expression of TM markers.74–78 It is well established that TGFβ2 and DEX induce the expression of ECM proteins in the TM. Here, we show that isolated MTM cells express fibronectin, collagen-1, collagen-4, laminin, and α-smooth

FIGURE 5. Ad5.Cre and Ad5.TGFβ2 increases fibronectin and collagen-1 expression in MTM cells. MTM cells (n = 3 replicates) were cultured to confluency and transduced overnight with Ad5.Null, Ad5.Cre, or Ad5.TGFβ2 at 100 MOI. After overnight incubation with the adenovirus, cells were cultured for 48 hours in serum-free medium. Ad5.Null had no effect on (A) BAMBI, (B) collagen-1, and (C) fibronectin expression. Ad5.Cre and Ad5.TGFβ2 decreased (D, G) BAMBI expression and increased (E, H) fibronectin and (F I) collagen-1 expression. (J, K) Densitometric analysis of conditioned medium showed that Ad5.Cre and Ad5.TGFβ2 increased fibronectin expression compared to Ad5.Null. Statistical significance was determined by 1-way ANOVA and Tukey post hoc analysis, *P < 0.05, **P < 0.01 (* compared to Ad5.Null).
muscle actin (Fig. 2). In addition, TGF
b (ng/mL) and DEX (100 lM) induce an increase in expression of these markers compared to their control treatments (Figs. 2A–T). Recently, we have shown that isolated mouse TM cells in culture respond to DEX treatment by upregulating myocilin expression and inducing the formation of CLANs. Here, DEX (100 lM) induced the expression of myocilin at 4 days after treatment compared to vehicle-treated cells (Figs. 3A, 3B). Recombinant human TGF
b (5 ng/mL) and DEX (100 lM) each induced the expression of CLANs compared to their controls (Figs. 3C–H). These data demonstrate that mouse TM cells can be isolated and cultured in vitro, express extracellular matrix proteins, and respond to TGF
b and DEX.

Knockdown of Bambi Increases ECM Expression

Adenovirus serotype 5 has selective tropism to the TM.79 Therefore, we evaluated the ability of isolated TM cells in culture to be transduced by Ad5.GFP using different MOI's (Fig. 4A). We observed that 200 MOI had the highest transduction efficiency; however, cells were visibly unhealthy and there was evidence of cell death. At 100 MOI, the cells were healthy and the majority of cells were GFP-positive. We also evaluated whether knockdown of Bambi leads to ECM changes in cultured MTM cells. Knockdown of Bambi using Ad5.Cre increased the levels of fibronectin and collagen-I in an MOI-dependent manner (Fig. 4B, Supplemental Fig. S2). Further, Ad5.TGF
b2 (100 MOI) and Ad5.Cre (100 MOI) decreased BAMBI (Figs. 5D, 5G) expression and increased fibronectin (Figs. 5E, 5H) and collagen-I (Figs. 5E, 5I) expression compared to Ad5.Null (100 MOI)-treated cells (Figs. 5A–C). Fibronectin expression in the conditioned medium also was quantified by Western blot (Figs. 5J, 5K). Fibronectin expression increased 2.74 ± 0.44-fold in the Ad5.Cre-treated cells and 2.12 ± 0.08-fold in the Ad5.TGF
b2-treated cells compared to the Ad5.Null-treated cells. These data provide evidence that BAMBI is an important regulator of the ECM in mouse TM cells.

Conditional Knockdown of Bambi in Mice Increases ECM Expression

BAMBI has been shown to be a regulator of growth factors involved in ECM remodeling.44,80–85 To evaluate the effects of BAMBI on ECM regulation in vivo, Bambi floxed mice were injected intravitreally with Ad5.Cre in one eye, while the
BAMBI Regulates ECM in the TM

Effects of Ad5.Null, Ad5.TGFβ2, and Ad5.Cre on IOP in B6.129S1-Bambitm1Jian/J mice. Mice were injected intravitreally with Ad5-null, Ad5.Cre, Ad5.TGFβ2, or Ad5.TGFβ2 + Ad5.Cre (2.5 × 10⁷ pfu). Day of injection was designated as day 0. The contralateral eye of each mouse was un.injected and served as a paired control. (A) Ad5.Null did not induce ocular hypertension at any time point compared to the contralateral eye (n = 7). (B-D) Injection with Ad5.Cre, Ad5.TGFβ2, or Ad5.TGFβ2 + Ad5.Cre each induced ocular hypertension starting at day 7 after injection and maintained significant IOP elevation throughout the 56-day time course compared to uninjected control eyes (P < 0.01, days 7–56). (B) At day 56 after injection, IOP increased to 29.8 ± 3.2 mm Hg in Ad5.Cre-injected eyes compared to 14.2 ± 0.3 mm Hg in contralateral uninjected eyes (P < 0.001, n = 9). (C) Ad5.TGFβ2 (32.3 ± 2.6 mm Hg) had significant IOP elevation at 56 days after injection compared to 14.2 ± 0.3 mm Hg in uninjected control eyes (P < 0.001, n = 10). (D) Ad5.TGFβ2 + Ad5.Cre (32.4 ± 3.9 mm Hg) had significant IOP elevation at 56 days after injection compared to uninjected control eyes (14.1 ± 0.5 mm Hg; P < 0.001, n = 10). Statistical significance was determined by Student’s paired t-test at each time point comparing the transduced eye to the contralateral uninjected control eye, ***P < 0.001, **P < 0.01, *P < 0.05 (* = compared to uninjected control).

Contralateral uninjected eye served as a control. Here, we show for the first time to our knowledge that the mouse TM expresses BAMBI, and Ad5.Cre transduction is sufficient to knockdown Bambi in the TM (n = 5; Fig. 6). We have shown previously that Ad5.TGFβ2 is able to increase the expression of fibronectin mRNA and protein in the TM of mice.20,21,55 We evaluated the importance of BAMBI in the regulation of ECM and used Ad5.TGFβ2 as a positive control. In our study, Ad5.Null (n = 7), Ad5.Cre (n = 15), and Ad5.TGFβ2 (n = 9) were used to transduce the TM of mice. Interestingly, knockdown of Bambi by Ad5.Cre or by Ad5.TGFβ2 increased the expression of fibronectin, collagen-1, and collagen-4 in the TM compared to Ad5.Null (Fig. 7).

Conditional Knockdown of Bambi Induces Ocular Hypertension in Mice

To test the effect of Bambi knockdown on ocular hypertension, Ad5.Null, Ad5.Cre, Ad5.TGFβ2, or Ad5.Cre + Ad5.TGFβ2 was injected intravitreally into B6.129S1-Bambitm1Jian/J mice (Figs. 8A–D). Our established mouse model of ocular hypertension using Ad5.TGFβ2 was used as our positive control.19–21 and Ad5.Null was used as a negative control. Ad5.Null, Ad5.Cre, Ad5.TGFβ2, or Ad5.Cre+Ad5.TGFβ2 viral vectors were injected intravitreally into one eye of each animal and the contralateral eye was used as an uninjected control. Ad5.Null did not elevate IOP at any time point (n = 7; Fig. 8A). Interestingly, knockdown of Bambi by Ad5.Cre significantly elevated IOP at all time points after injection compared to the uninjected control eyes (Fig. 8B; P < 0.01, n = 9). At day 56, IOP in the Ad5.Cre-injected eyes reached 29.8 ± 3.2 mm Hg compared to the contralateral uninjected eye, 14.2 ± 0.3 mm Hg (P < 0.001). As expected, Ad5.TGFβ2 had significant IOP elevation at all time points after injection compared to the uninjected control eyes (Fig. 8C; P < 0.001, n = 10). At day 56, IOP in the Ad5.TGFβ2-injected eyes reached 32.3 ± 2.6 mm Hg compared to the contralateral uninjected eye, 14.2 ± 0.3 mm Hg (P < 0.001). Ad5.TGFβ2 + Ad5.Cre also significantly elevated IOP at all time points (Fig. 8D; P < 0.01, n = 10). At day 56, IOP in the Ad5.TGFβ2 + Ad5.Cre injected eyes reached 32.4 ± 3.9 mm Hg compared to the contralateral uninjected eyes, 14.1 ± 0.3 mm Hg (P < 0.001). These data suggest that knockdown of Bambi is sufficient to cause ocular hypertension in mice to the same degree as overexpression of TGFβ2. Cotreatment of Ad5.TGFβ2 + Ad5.Cre did not produce additional IOP elevation above that of Ad5.Cre or Ad5.TGFβ2 alone, suggesting that we may have reached the maximum IOP elevation for this experimental paradigm. Statistical significance was determined by Student’s paired t-test at each time point comparing the transduced eye to the contralateral uninjected control eye.
DISCUSSION

In this study, we demonstrate that BAMBI is a novel regulator of the ECM and fibrosis in the TM. Isolated MTM cells from B6.129S1-Bambi<sup>tm1Jian</sup>/J mice express TM markers and knockdown of BAMBI in these cells increased ECM protein expression. Interestingly, knockdown of BAMBI in the TM of mice elevated IOP reduced outflow facility, and increased ECM proteins in the TM. These findings suggest that BAMBI has an important role in TM ECM and IOP regulation.

Regulatory mechanisms to control TGFβ signaling have been shown to affect directly the TGFβ receptors and downstream signaling molecules. BAMBI has been identified as an important regulator of TGFβ signaling. The extracellular domain of BAMBI is related closely to type-I TGFβ and BMP receptors. However, BAMBI has been shown to have two serine/threonine kinase domains, thus inhibiting TGFβ and BMP signaling. TGFβ and BMP signaling have been shown to regulate ECM production and regulation of the ECM in the TM. These data suggest that the ECM and fibrosis are important regulators of TGFβ signaling.

We have shown that TGFβ signaling in the TM is important in regulating ECM production. Recent evidence suggests that TGFβ signaling can directly increase BAMBI mRNA and protein levels upon TGFβ2-induced ocular hypertension. These data suggest that the ECM and fibrosis are important regulators of TGFβ signaling.

Conclusively, we demonstrate that BAMBI is involved in the production and regulation of the ECM in the TM. These data suggest that TGFβ signaling in the TM is important in regulating ECM production. Recent evidence suggests that TGFβ signaling can directly increase BAMBI mRNA and protein levels upon TGFβ2-induced ocular hypertension. These data suggest that the ECM and fibrosis are important regulators of TGFβ signaling.

**CONCLUSIONS**

In summary, we demonstrate that BAMBI is involved in the production and regulation of the ECM in the TM. These data suggest that TGFβ signaling in the TM is important in regulating ECM production. Recent evidence suggests that TGFβ signaling can directly increase BAMBI mRNA and protein levels upon TGFβ2-induced ocular hypertension. These data suggest that the ECM and fibrosis are important regulators of TGFβ signaling.
provide evidence that BAMBI is a critical link molecule in TGFβ2-TLR4 signaling crosstalk. Our data further provide a new insight into the molecular mechanism involved in the development of glaucomatous TM damage.

**Acknowledgments**

Supported by the Bright Focus Foundation G2014063 (CMM), National Institutes of Health R01EY026529 (CMM), and Neurobiology of Aging Training Grant T32AG020494 (HH).

Disclosure: H. Hernandez, None; J.C. Millar, None; S.M. Curry, None; A.F. Clark, None; C.M. McDowell, None

**References**

BAMBI Regulates ECM in the TM

Investigative Ophthalmology & Visual Science


BAMBI Regulates ECM in the TM


